Timothy Rolph Akero Therapeutics, Inc. (AKRO) insider trading activity

Timothy Rolph is Chief Scientific Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 178,337 shares of AKRO, which is worth approximately $5.06 Million. The most recent transaction as insider was on Dec 17, 2024, when has been sold 3,800 shares (Common Stock) at a price of $31.1 per share, resulting in proceeds of $118,180. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 178K

1.31% 3M change

2.37% 12M change

Total Value Held $5.06 Million

Timothy Rolph Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 17 2024	SELL Open market or private sale	$118,180 $31.1 p/Share	3,800 Reduced 2.09%	178,337 Common Stock
Dec 17 2024	BUY Exercise of conversion of derivative security	$75,506 $19.87 p/Share	3,800 Added 2.04%	182,137 Common Stock
Dec 16 2024	BUY Grant, award, or other acquisition	-	20,000 Added 9.16%	198,337 Common Stock
Dec 10 2024	SELL Open market or private sale	$148,924 $30.91 p/Share	4,818 Reduced 2.63%	178,337 Common Stock
Dec 10 2024	BUY Exercise of conversion of derivative security	$48,681 $19.87 p/Share	2,450 Added 1.34%	180,787 Common Stock
Sep 10 2024	SELL Open market or private sale	$14,058 $26.18 p/Share	537 Reduced 0.3%	180,705 Common Stock
Jun 28 2024	BUY Grant, award, or other acquisition	$21,216 $19.94 p/Share	1,064 Added 0.58%	181,242 Common Stock
Jun 11 2024	SELL Open market or private sale	$53,883 $22.64 p/Share	2,380 Reduced 1.3%	180,178 Common Stock
Mar 13 2024	SELL Open market or private sale	$17,536 $28.33 p/Share	619 Reduced 0.34%	182,558 Common Stock
Dec 14 2023	SELL Open market or private sale	$10,670 $20.76 p/Share	514 Reduced 0.28%	182,672 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	32,497 Added 15.07%	183,186 Common Stock
Sep 13 2023	SELL Open market or private sale	$26,730 $50.34 p/Share	531 Reduced 0.35%	150,689 Common Stock
Jun 16 2023	SELL Open market or private sale	$4,326,024 $55.32 p/Share	78,200 Reduced 34.09%	151,220 Common Stock
Jun 16 2023	BUY Exercise of conversion of derivative security	$24,400 $0.61 p/Share	40,000 Added 14.85%	229,420 Common Stock
Jun 13 2023	SELL Open market or private sale	$28,076 $55.16 p/Share	509 Reduced 0.27%	189,420 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$26,212 $43.47 p/Share	603 Reduced 0.32%	189,929 Common Stock
Dec 29 2022	SELL Open market or private sale	$1,035,506 $50.97 p/Share	20,316 Reduced 9.64%	190,532 Common Stock
Dec 29 2022	BUY Exercise of conversion of derivative security	$221,583 $28.35 p/Share	7,816 Added 3.57%	210,848 Common Stock
Dec 28 2022	SELL Open market or private sale	$85,000 $50.0 p/Share	1,700 Reduced 0.83%	203,032 Common Stock
Dec 28 2022	BUY Exercise of conversion of derivative security	$48,195 $28.35 p/Share	1,700 Added 0.82%	204,732 Common Stock
Dec 09 2022	BUY Grant, award, or other acquisition	-	19,195 Added 8.64%	203,032 Common Stock
Nov 16 2022	SELL Open market or private sale	$180,575 $45.75 p/Share	3,947 Reduced 2.1%	183,837 Common Stock
Nov 15 2022	SELL Open market or private sale	$141,335 $45.04 p/Share	3,138 Reduced 1.64%	187,784 Common Stock
Oct 26 2022	SELL Open market or private sale	$214,433 $45.03 p/Share	4,762 Reduced 2.43%	190,922 Common Stock
Oct 25 2022	SELL Open market or private sale	$480,344 $45.09 p/Share	10,653 Reduced 5.16%	195,684 Common Stock

Timothy Rolph

Chief Scientific Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account